CADTH Canadian Drug Expert Committee recommendation : indication : for use in combination with methotrexate (MTX) for the treatment of adult patients with moderate to severe rheumatoid arthritis (RA) who have responded inadequately to one or more disease-modifying anti-rheumatic drugs (DMARDs) : baricitinib may also be used as monotherapy in cases of intolerance to MTXBaricitinib (Olumiant -- Eli Lilly Canada Inc.)
The CADTH Canadian Drug Expert Committee (CDEC) recommends that baricitinib be reimbursed for use in combination with MTX for the treatment of adult patients with moderate to severe RA who have responded inadequately to one or more DMARDs, if the following conditions are met : Conditions for Reimbursement Initiation Criteria 1. Adult patients with moderately-to-severely active RA on stable doses of DMARDs who have had inadequate response or intolerance to one or more DMARDs. 2. Baricitinib should only be used in combination with MTX (alone or with other conventional DMARDs [cDMARDs]). 3. Baricitinib should not be used in combination with other biologic DMARDs (bDMARDs), including Janus kinase (JAK) inhibitors..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
August 2019 |
|---|---|
| Erschienen: |
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health ; August 2019 |
| Ausgabe: |
Version: 1.0. |
| Reihe: |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
www.ncbi.nlm.nih.gov [teilw. kostenfrei] |
|---|
| Themen: |
Arthritis, Rheumatoid |
|---|
| Anmerkungen: |
"Final.". - Description based on online resource; title from PDF title page (viewed March 9, 2020) |
|---|
| Umfang: |
1 online resource (1 PDF file (8 pages)) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
177318783X |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 177318783X | ||
| 003 | DE-627 | ||
| 005 | 20230428011936.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211011s2019 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)177318783X | ||
| 035 | |a (DE-599)KEP068712154 | ||
| 035 | |a (NCBI)9917601053406676 | ||
| 035 | |a (EBP)068712154 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 110 | 2 | |a CADTH Canadian Drug Expert Committee, |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CADTH Canadian Drug Expert Committee recommendation |b indication : for use in combination with methotrexate (MTX) for the treatment of adult patients with moderate to severe rheumatoid arthritis (RA) who have responded inadequately to one or more disease-modifying anti-rheumatic drugs (DMARDs) : baricitinib may also be used as monotherapy in cases of intolerance to MTXBaricitinib (Olumiant -- Eli Lilly Canada Inc.) |
| 250 | |a Version: 1.0. | ||
| 264 | 1 | |a Ottawa (ON) |b Canadian Agency for Drugs and Technologies in Health |c August 2019 | |
| 300 | |a 1 online resource (1 PDF file (8 pages)) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a CADTH common drug review | |
| 500 | |a "Final.". - Description based on online resource; title from PDF title page (viewed March 9, 2020) | ||
| 520 | |a The CADTH Canadian Drug Expert Committee (CDEC) recommends that baricitinib be reimbursed for use in combination with MTX for the treatment of adult patients with moderate to severe RA who have responded inadequately to one or more DMARDs, if the following conditions are met : Conditions for Reimbursement Initiation Criteria 1. Adult patients with moderately-to-severely active RA on stable doses of DMARDs who have had inadequate response or intolerance to one or more DMARDs. 2. Baricitinib should only be used in combination with MTX (alone or with other conventional DMARDs [cDMARDs]). 3. Baricitinib should not be used in combination with other biologic DMARDs (bDMARDs), including Janus kinase (JAK) inhibitors. | ||
| 650 | 2 | |a Arthritis, Rheumatoid |x drug therapy |0 https://id.nlm.nih.gov/mesh/D001172Q000188 | |
| 650 | 2 | |a Azetidines |x therapeutic use |0 https://id.nlm.nih.gov/mesh/D001384Q000627 | |
| 650 | 2 | |a Sulfonamides |x therapeutic use |0 https://id.nlm.nih.gov/mesh/D013449Q000627 | |
| 650 | 2 | |a Insurance, Health, Reimbursement |0 https://id.nlm.nih.gov/mesh/D007349 | |
| 651 | 2 | |a Canada |0 https://id.nlm.nih.gov/mesh/D002170 | |
| 710 | 2 | |a Canadian Agency for Drugs and Technologies in Health, |e MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/books/NBK549614/ |m X:NCBI |x Verlag |z teilw. kostenfrei |
| 912 | |a ZDB-193-NCB | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a ISIL_DE-18 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_22_i06404 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a ISIL_DE-7 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a ISIL_DE-354 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a ISIL_DE-180 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a ISIL_DE-15 | ||
| 951 | |a BO | ||
| 980 | |2 22 |1 01 |x 0018 |b 3994084849 |h h64 NCBI |y zi06404 |z 21-10-21 | ||
| 980 | |2 40 |1 01 |x 0007 |b 3994011108 |h OLR-NCB-BOOKSHELF |y xsn |z 21-10-21 | ||
| 980 | |2 74 |1 01 |x 0354 |b 3999787376 |c 09 |f E-Bibl |d EM 0000 |e --%%-- |j --%%-- |y ze |z 08-11-21 | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 3995680755 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 25-10-21 | ||
| 980 | |2 2009 |1 01 |x DE-180 |b 3987677511 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 11-10-21 | ||
| 980 | |2 2010 |1 01 |x DE-15 |b 3987767278 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 11-10-21 | ||
| 981 | |2 22 |1 01 |x 0018 |r https://www.ncbi.nlm.nih.gov/books/NBK549614/ | ||
| 981 | |2 40 |1 01 |x 0007 |y Volltext, Open Access |r https://www.ncbi.nlm.nih.gov/books/NBK549614/ | ||
| 981 | |2 74 |1 01 |x 0354 |r https://www.ncbi.nlm.nih.gov/books/NBK549614/ | ||
| 981 | |2 2003 |1 01 |x DE-25 |r https://www.ncbi.nlm.nih.gov/books/NBK549614/ | ||
| 981 | |2 2010 |1 01 |x DE-15 |y Online-Zugriff |r https://www.ncbi.nlm.nih.gov/books/NBK549614/ | ||
| 985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
| 985 | |2 74 |1 01 |x 0354 |a EM 0000 | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 NCBI | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 freie Ressource | ||
| 995 | |2 40 |1 01 |x 0007 |a OLR-NCB-BOOKSHELF | ||